US Patent

US11883374 — Lacosamide pharmaceutical composition and dosage form thereof

Method of Use · Assigned to Shanghai Aucta Pharmaceuticals Co Ltd · Expires 2040-06-05 · 14y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition and dosage form of lacosamide, specifically an extended release form, for treating neurological or psychiatric diseases or conditions.

USPTO Abstract

A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.

Drugs covered by this patent

Vimpat (lacosamide) · UCB

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3954`	—	Vimpat
`U-3954`	—	Vimpat
`U-3660`	—	Vimpat

Patent Metadata

Patent number: US11883374
Jurisdiction: US
Classification: Method of Use
Expires: 2040-06-05
Drug substance claim: No
Drug product claim: Yes
Assignee: Shanghai Aucta Pharmaceuticals Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.